Article Menu
Need Help?
No Article Versions Notes Found
Cite
Kansal, A.R.; Reifsnider, O.S.; Brand, S.B.; Hawkins, N.; Coughlan, A.; Li, S.; Cragin, L.; Paramore, C.; Dietz, A.C.; Caro, J.J. Economic Evaluation of Betibeglogene Autotemcel (Beti-Cel) Gene Addition Therapy in Transfusion-Dependent β-Thalassemia. J. Mark. Access Health Policy 2021, 9, 1922028. https://doi.org/10.1080/20016689.2021.1922028
Kansal AR, Reifsnider OS, Brand SB, Hawkins N, Coughlan A, Li S, Cragin L, Paramore C, Dietz AC, Caro JJ. Economic Evaluation of Betibeglogene Autotemcel (Beti-Cel) Gene Addition Therapy in Transfusion-Dependent β-Thalassemia. Journal of Market Access & Health Policy. 2021; 9(1):1922028. https://doi.org/10.1080/20016689.2021.1922028
Chicago/Turabian StyleKansal, Anuraag R., Odette S. Reifsnider, Sarah B. Brand, Neil Hawkins, Anna Coughlan, Shujun Li, Lael Cragin, Clark Paramore, Andrew C. Dietz, and J. Jaime Caro. 2021. "Economic Evaluation of Betibeglogene Autotemcel (Beti-Cel) Gene Addition Therapy in Transfusion-Dependent β-Thalassemia" Journal of Market Access & Health Policy 9, no. 1: 1922028. https://doi.org/10.1080/20016689.2021.1922028
APA StyleKansal, A. R., Reifsnider, O. S., Brand, S. B., Hawkins, N., Coughlan, A., Li, S., Cragin, L., Paramore, C., Dietz, A. C., & Caro, J. J. (2021). Economic Evaluation of Betibeglogene Autotemcel (Beti-Cel) Gene Addition Therapy in Transfusion-Dependent β-Thalassemia. Journal of Market Access & Health Policy, 9(1), 1922028. https://doi.org/10.1080/20016689.2021.1922028
